Inside the Hsp90 inhibitors binding mode through induced fit docking

Journal of Molecular Graphics and Modelling

Volumn 27, Issue 6, 2009, Pages 712-722

  Lauria, Antonino ^a   Ippolito, Mario ^a   Almerico, Anna Maria ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Geldanamicyn; Heat shock protein; Induced fit; Molecular docking; Radicicol

Indexed keywords

GELDANAMICYN; HEAT SHOCK PROTEIN; INDUCED FIT; MOLECULAR DOCKING; RADICICOL;

BINDING ENERGY; HYDROGEN; MOLECULAR MODELING; MOLECULES; PLANNING; PROTEINS; STRATEGIC PLANNING;

DOCKING;

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 3 (5 CHLORO 2,4 DIHYDROXYPHENYL) N ETHYL 4 (4 METHOXYPHENYL) 5 PYRAZOLECARBOXAMIDE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HYDROGEN; ISOXAZOLE 40F; PURINE 8; RADICICOL; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; CONFORMATION; DRUG BINDING; PRIORITY JOURNAL; PROTEIN INTERACTION; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; BENZOQUINONES; BINDING SITES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HSP90 HEAT-SHOCK PROTEINS; LACTAMS, MACROCYCLIC; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROTEIN BINDING; SEQUENCE ALIGNMENT;

EID: 58849127710     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2008.11.004     Document Type: Article

References (41)

1. Srivastava P.K., and Maki R.G. Stress-induced proteins in immune response to cancer. Curr. Top. Microbiol. Immunol. 167 (1991) 109-123
2. Ciocca D.R., Fuqua S.A.W., Lock-Lim S., Toft D.O., Welch W.J., and McGuire W.L. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res. 52 (1992) 3648-3654
3. Xu Y., and Lindquist S. Heat-shock protein hsp90 governs the activity of pp60v-src kinase. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 7074-7078
4. Minet E., Mottet D., Michel G., Roland I., Raes M., Remacle J., and Michiels C. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett. 460 (1999) 251-256
5. Ferrarini M., Heltai S., Zocchi M.R., and Rugarli C. Unusual expression and localization of heat shock proteins in human tumor cells. Int. J. Cancer 51 (1992) 613-619
6. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8 (2002) S55-S61
7. Isaacs J.S., Xu W., and Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3 (2003) 213-217
8. Scheibel T., and Buchner J. The Hsp90 complex-a super-chaperone machine as a novel drug target. Biochem. Pharmacol. 56 (1998) 675-682
9. Hernandez M.P., Sullivan W.P., and Toft D.O. The assembly and intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex. J. Biol. Chem. 277 (2002) 38294-38304
10. DeBoer C., Meulman P.A., Wnuk R.J., and Peterson D.H. Geldanamycin, a new antibiotic. J. Antibiot. 23 (1970) 442-447
11. Supko J.G., Hickman R.L., Grever M.R., and Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 36 (1997) 305-315
12. Egorin M.J., Lagattuta T.F., Hamburger D.R., Covey J.M., White K.D., Musser S.M., and Eiseman J.L. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother. Pharmacol. 49 (2002) 7-19
13. http://clinicaltrials.gov/ct2/show/NCT00506805
14. Dymock B.W., Drysdale M.J., McDonald E., and Workman P. Inhibitors of HSP90 and other chaperones for the treatment of cancer. Expert Opin. Ther. Pat. 14 (2004) 837-847
15. Neckers L., and Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics-an update. Expert Opin. Emerging Drugs 10 (2005) 137-149
16. http://www.pdb.org
17. Scherman W., Day T., Jacobson M.P., Friesner R.A., and Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 49 (2006) 534-553
18. Liu T., Lin Y., Wen X., Jorrisen R.N., and Gilson M.K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 35 (2007) D198-D201
19. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., and Pavletich N.P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89 (1997) 239-250
20. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., and Pearl L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42 (1999) 260-266
21. Barril X., Brough P., Drysdale M., Hubbard R.E., Massey A., Surgenor A., and Wright L. Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 5187-5191
22. Dymock B.W., Barril X., Brough P.A., Cansfield J.E., Massey A., McDonald E., Hubbard R.E., Surgenor A., Roughley S.D., Webb P., Work man P., Wright L., and Drysdale M.J. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J. Med. Chem. 48 (2005) 4212-4215
23. Cheung K.M.J., Mattews T.P., James K., Rowlands M.G., Boxall K.J., Sharp S.Y., Maloney A., Roe S.M., Prodromou C., Pearl L.H., Aherne G.W., McDonald E., and Workman P. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 3338-3343
24. Wright L., Barril X., Dymock B., Sheridan L., Surgenor A., Beswich M., Drysdale M., Collier A., Massey A., Davies N., Fink A., Fromont C., Aherne W., Boxall K., Sharp S., Workman P., and Hubbard R.E. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem. Biol. 11 (2004) 775-785
25. Brough P.A., Aherne W., Barril X., Borgognoni J., Boxall K., Cansfield J.E., Cheung K.M.J., Collins I., Davies N.G.M., Drysdale M.J., Dymock B., Eccles S.A., Finch H., Fink A., Hayes A., Howes R., Hubbard R.E., James K., Jordan A.M., Lockie A., Martins V., Massey A., Mattews T.P., McDonald E., Northfield C.J., Pearl L.H., Prodromou C., Ray S., Raynaud F.I., Roughley S.D., Sharp S.Y., Surgenor A., Walmsey D.L., Webb P., Wood M., Workman P., and Wright L. 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J. Med. Chem. 51 (2008) 196-218
26. Prodromou C., Roe S.M., O'Brien R., Ladbury J.E., Piper P.W., and Pearl L.H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90 (1997) 65-75
27. SiteMap, version 2.1, Scrödinger, LLC, New York, NY, 2007.
28. Halperin I., Ma B., Wolfson H., and Nussinov R. Principles of docking: an overview of search algorithms and a guide to scoring functions. Proteins 47 (2002) 409
29. Sousa S.P., Fernandes P.A., and Ramos M.J. Protein-ligand docking: current status and future challenges. Proteins 65 (2006) 15
30. Janin J., and Cherfils J. Protein docking algorithms: Simulating molecular recognition. Curr. Opin. Struct. Biol. 3 (1993) 265
31. Kokh D.B., and Wenzel W. Flexible side chain models improve enrichment rates in silico screening. J. Mol. Med. 51 (2008) 5919
32. Knegtel R.M.A., Kuntz I.D., and Oshiro C.M. Molecular docking to ensembles of protein structures. J. Mol. Biol. 266 (1997) 424
33. Sudbeck E.A., Mao C., Venkatachalam T.K., Thuel-Ahlgren L., and Uckum F.M. Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase. Antimicrob. Agents Chemother. 42 (1998) 3225
34. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hartl W.E., Belew R.K., and Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19 (1998) 1639
35. Pak Y.S., and Wang S. Application of a molecular dynamics simulation method with a generalized effective potential to the flexible molecular docking problems. J. Phys. Chem. B 104 (2000) 354
36. Glide, version 4.5, Scrödinger, LLC, New York, NY, 2005.
37. Prime, version 1.6, Scrödinger, LLC, New York, NY, 2005.
38. Lovell S.C., Davis I.W., Arendall W.B., De Bakker P.I.W., Word J.M., Prisant M.G., Richardson J.S., and Richardson D.C. Structure validation by C-alpha geometry: phi, psi, and C-beta deviation. Prot. Struct. Funct. Gen. 50 (2002) 437-450
39. Chiosis G., Timaul M.N., Lucas B., Munster P.N., Zheng F.F., Sepp-Lorenzino L., and Rosen N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 8 (2001) 289-299
40. Barril X., Hubbard R.E., and Morley S.D. Virtual screening in structure-based drug discovery. Mini Rev. Med. Chem. 4 (2004) 779-791
41. Brough P.A., Barril X., Beswick M., Dymock B.W., Drysdale M.J., Wright L., Grant K., Massey A., Surgenor A., and Workman P. 3-(5-Chloro-2, 4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone. Bioorg. Med. Chem. Lett. 15 (2005) 5197-5201